Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Zymedi Logo
Zymedi Growth Score
58
CB Rank
109601
Heat Score
69
Zymedi is a pharmaceutical company that develops drugs for life-threatening diseases.
Founded
obfuscation
PrivateSeries A Ansan, Inch'on-jikhalsi, South Korea11-50 zymedi.com
Biotechnology
Health Care
Pharmaceutical
Therapeutics
Overview

Zymedi
Total Funding
obfuscation
Growth Score
58
Heat Score
69

Total Funding
obfuscation
obfuscation
Series A raised
obfuscation
Growth Score58
-33 pts
in past quarter
Heat Score 69
-15 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Zymedi

CB Rank
109601
Zymedi is a pharmaceutical company that develops drugs for life-threatening diseases.
Founded
obfuscation
PrivateSeries A Ansan, Inch'on-jikhalsi, South Korea11-50 zymedi.com
Biotechnology
Health Care
Pharmaceutical
Therapeutics

Funding Rounds

Series A
OBF
in
obfuscation
Venture - Series Unknown
OBF
in
obfuscation

Details

Legal Name Zymedi
Also Known As 자이메디
Operating Status Active
Company Type For Profit
Phone Number +82 32 822 8376
Contact Email info@zymedi.com
Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

ZMA001
A monoclonal antibody targeting KARS1 to treat pulmonary arterial hypertension by inhibiting inflammation in pulmonary blood vessels.
ZMC001
A small molecule compound that selectively inhibits KARS1 to address inflammatory pathways in metabolic dysfunction-associated steatohepatitis.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 2
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Series A - Zymedi Logo
Series A - Zymedi
6
obfuscation
— Series A
obfuscation
Series A - Zymedi Logo
Series A - Zymedi
6
obfuscation
— Series A
obfuscation
Series A - Zymedi Logo
Series A - Zymedi
6
obfuscation
— Series A
obfuscation
Series A - Zymedi Logo
Series A - Zymedi
6
obfuscation
— Series A
obfuscation
Series A - Zymedi Logo
Series A - Zymedi
6
obfuscation
— Series A

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 2
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Series A - Zymedi Logo
Series A - Zymedi
6
obfuscation
— Series A
obfuscation
Series A - Zymedi Logo
Series A - Zymedi
6
obfuscation
— Series A
obfuscation
Series A - Zymedi Logo
Series A - Zymedi
6
obfuscation
— Series A
obfuscation
Series A - Zymedi Logo
Series A - Zymedi
6
obfuscation
— Series A
obfuscation
Series A - Zymedi Logo
Series A - Zymedi
6
obfuscation
— Series A

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
CKD Venture Capital Corporation Logo
CKD Venture Capital Corporation
—
Series A - Zymedi Logo
Series A - Zymedi
—
CKD Venture Capital Corporation Logo
CKD Venture Capital Corporation
—
Series A - Zymedi Logo
Series A - Zymedi
—
CKD Venture Capital Corporation Logo
CKD Venture Capital Corporation
—
Series A - Zymedi Logo
Series A - Zymedi
—
CKD Venture Capital Corporation Logo
CKD Venture Capital Corporation
—
Series A - Zymedi Logo
Series A - Zymedi
—
CKD Venture Capital Corporation Logo
CKD Venture Capital Corporation
—
Series A - Zymedi Logo
Series A - Zymedi
—
Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Contacts 2
News

News and Press

News•Feb 16, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Dec 8, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Aug 26, 2024
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

120

Active Website Tech Count

3Zymedi is actively using 3 technologies for its website, according to BuiltWith. These include Common Crawl, CommonCrawl Top 50m, and  Euro.

Total IP

12The intellectual property of Zymedi includes 12 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Zymedi's headquarters? Zymedi is located in Ansan, Inch'on-jikhalsi, South Korea.Who invested in Zymedi? Zymedi has 7 investors including CKD Venture Capital Corporation and  Korea Venture Investment Corp.When was the last funding round for Zymedi? Zymedi closed its last funding round on
obfuscation
from a Series A round.Who are Zymedi's competitors? Alternatives and possible competitors to Zymedi may include Eli Lilly, Pfizer, and  Gilead Sciences.How much funding has Zymedi raised to date? Zymedi has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(5eb04bf 1)
|